Skip to main content

Table 2 Medical and health variables of the study

From: Judicialization of health: profile of demands for oncological medicines in a state in the central region of Brazil

Variables All groups TJGO TRF (GO)
n % n % n %
Drug 301 100% 264 88% 37 12%
 temozolamide 42 14% 41 14% 1 0%
 bevacizumab 39 13% 33 11% 6 2%
 rituximab 26 9% 24 8% 2 1%
 pazopanib 25 8% 18 6% 7 2%
 pembrolizumab 15 5% 15 5% 0 0%
 ibrutinib 15 5% 14 5% 1 0%
 bortezomib 10 3% 9 3% 1 0%
 Others 129 43% 110 37% 19 6%
ICD-10a 301 100% 264 88% 37 12%
 C-71malignant neoplasm of brain 40 13.3% 39 13% 1 0.3%
 C-90 multiple myeloma and malignant plasma cell neoplasms 38 12.7% 33 11% 5 1.7%
 C-53 malignant neoplasm of cervix uterin 28 9.3% 24 8% 4 1.3%
 C-64 malignant neoplasm of kidney, except renal pelvis 26 9% 20 7% 6 2.0%
 C-43 malignant melanoma of skin 15 5% 15 5% 0 0.0%
 C-91 lymphoid leukemia 15 5% 12 4% 3 1.0%
 C-18 malignant neoplasm of colon 13 4.3% 12 4% 1 0.3%
 C-50 malignant neoplasm of breast 12 3.7% 10 3% 2 0.7%
 C-81 Hodgkin lymphoma 8 2.7% 3 1% 5 1.7%
 C-82 Follicular lymphoma 5 2% 5 2% 0 0.0%
 Others 101 33.3% 91 30% 10 3.3%
Origin of the report 301 100% 264 88% 37 12%
 Public 271 90% 237 78% 34 11%
 Private 30 10% 27 9% 3 1%
  1. aICD-10: International Classification of Diseases, version 10 [58]